PKD DIET

Tesevatinib

Tesevatinib ARPKD Useful in Animal Studies

Tesevatinib ADPKD still in clinical trials

Tesevatinib is tyrosine kinase inhibitor for the treatment of polycystic kidney disease. Tesevatinib is well tolerated and can be taken once a day tesevatinib 50 mg as the optimal dose to treat ADPKD. At UCLA in the US, clinical trials for ADPKD will be tried. It increases serum creatinine (not usually a good thing in PKD), but while taking Tesevatinib this was thought to not effect PKD kidney functioning. New data demonstrated that serum creatinine levels in tesevatinib patients increased by 10% to 14% during the first 28 days of treatment and reversed upon treatment discontinuation. Importantly, levels of cystatin C, another measure of renal function, were relatively unchanged during the same period.

MATE 1/2-K inhibitors (Tesevatinib), this increases serum creatinine which occurs without clinically meaningful alterations in renal function.

We are  sharing our experiences with PKD/PLD Diet, an adjunct diet envisioning it complementing a physician's prescribed medical therapy. Consider testing this with your doctor's prior knowledge, who can  adjust it according to your own uniqueness by adding it to your current  treatment.

Medical Disclaimer